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Abstract. Intrinsic resistance to the epidermal growth factor
receptor (EGFR; HER1) tyrosine kinase inhibitor (TKI)
gefitinib, and more generally to EGFR TKIs, is a common
phenomenon in breast cancer. The availability of molecular
criteria for predicting sensitivity to EGFR-TKIs is, therefore,
the most relevant issue for their correct use and for planning
future research. Though it appears that in non-small-cell lung
cancer (NSCLC) response to gefitinib is directly related to
the occurrence of specific mutations in the EGFR TK domain,
breast cancer patients cannot be selected for treatment with
gefitinib on the same basis as such EGFR mutations have been
reported neither in primary breast carcinomas nor in several
breast cancer cell lines. Alternatively, there is a general
agreement on the hypothesis that the occurrence of molecular
alterations that activate transduction pathways downstream
of EGFR (i.e., MEK1/MEK2  ERK1/2 MAPK and PI-3'K 
AKT growth/survival signaling cascades) significantly affect
the response to EGFR TKIs in breast carcinomas. However,
there are no studies so far addressing a role of EGF-related
ligands as intrinsic breast cancer cell modulators of EGFR TKI
efficacy. We recently monitored gene expression profiles and
sub-cellular localization of HER-1/-2/-3/-4 related ligands (i.e.,
EGF, amphiregulin, transforming growth factor-α, ß-cellulin,
epiregulin and neuregulins) prior to and after gefitinib treatment
in a panel of human breast cancer cell lines. First, gefitinib-
induced changes in the endogenous levels of EGF-related
ligands correlated with the natural degree of breast cancer cell
sensitivity to gefitinib. While breast cancer cells intrinsically
resistant to gefitinib (IC50 ≥15 μM) markedly up-regulated
(up to 600 times) the expression of genes codifying for HER-
specific ligands, a significant down-regulation (up to 106 times)
of HER ligand gene transcription was found in breast cancer
cells intrinsically sensitive to gefitinib (IC50 ≤1 μM). Second,
loss of HER1 function differentially regulated the nuclear
trafficking of HER-related ligands. While gefitinib treatment
induced an active import and nuclear accumulation of the
HER ligand NRG in intrinsically gefitinib-resistant breast
cancer cells, an active export and nuclear loss of NRG was
observed in intrinsically gefitinib-sensitive breast cancer cells.
In summary, through in vitro and pharmacodynamic studies
we have learned that, besides mutations in the HER1 gene,
oncogenic changes downstream of HER1 are the key players
regulating gefitinib efficacy in breast cancer cells. It now
appears that pharmacological inhibition of HER1 function
also leads to striking changes in both the gene expression and
the nucleo-cytoplasmic trafficking of HER-specific ligands,
and that this response correlates with the intrinsic degree of
breast cancer sensitivity to the EGFR TKI gefitinib. The
relevance of this previously unrecognized intracrine feedback
to gefitinib warrants further studies as cancer cells could bypass
the antiproliferative effects of HER1-targeted therapeutics
without a need for the overexpression and/or activation of other
HER family members and/or the activation of HER-driven
downstream signaling cascades. 
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1. Gefitinib and breast cancer: A disappointing history
The epidermal growth factor receptor (EGFR; HER1) and its
cognate ligands have been shown to actively contribute to the
pathogenesis and progression of breast cancer (1-4). This
evidence led to the development of different anti-EGFR agents,
and several have undergone clinical trials, including the small
molecule tyrosine kinase inhibitor (TKI) gefitinib (Iressa;
AstraZeneca, Macclesfield, UK). Gefitinib is a low molecular
weight inhibitor with highly selective and reversible TK
inhibition properties directed at the EGFR, being a competitive
inhibitor of adenosine triphosphate binding to this receptor
(5-6).
Initial phase II studies have suggested that gefitinib does
not have a high efficacy in a heavily pre-treated population
of patients with metastatic breast cancer, particularly post
chemotherapy (7). With the exception of a recent neoadjuvant
trial in estrogen receptor (ER)-positive breast cancer patients
(8), clinical studies of the EGFR TKI gefitinib in breast cancer
resulted in few clinical responses and in a disease control rate
of approximately 10% (7,9). These observations clearly indicate
that intrinsic resistance to gefitinib, and more generally to
EGFR TKIs, is a common phenomenon in breast cancer (7). 
2. How breast cancer cells escape the anti-tumor effects
of gefitinib
Unraveling the ultimate molecular mechanisms determining
the resistance/sensitivity of breast cancer cells to gefitinib is
a major challenge that is only beginning to be addressed. It
has been recently demonstrated that in non-small-cell lung
cancer (NSCLC) response to gefitinib is directly related to
the occurrence of specific mutations in the EGFR TK domain
(10-13; Fig. 1a). Unfortunately, breast cancer patients cannot
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Figure 1. Mechanisms of cancer resistance to Gefitinib (Iressa). (a) HER1 mutations. (b) The ‘AKT hypothesis’ for breast cancer resistance to gefitinib.
(c) The ‘MEK/MAPK hypothesis’ for breast cancer resistance to gefitinib. (d and e) Up-regulation of EGF-related ligands: a novel mode for breast cancer
resistance to gefitinib. Our current findings reveal that gefitinib-induced changes in the expression pattern of genes codifying for EGF-related ligands
strikingly correlate with the intrinsic degree of sensitivity of breast cancer cells to the antiproliferative effects of gefitinib; i.e., gefitinib-resistant and gefitinib-
sensitive breast cancer cells markedly up-regulate and down-regulate, respectively, the expression of genes codifying for EGF-related ligands. Therefore,
activation/deactivation of HER-ligand gene clusters appears to balance loss of HER1-receptor function in breast cancer cells. Moreover, pharmacological
blockade of HER1 TK activity differentially regulates an active nuclear import/export of EGF-related ligands in gefitinib-sensitive and gefitinib-resistant
breast cancer cells. Since EGF-related ligands may function through intracrine, paracrine and/or autocrine pathways to control cell proliferation and survival
in breast cancer cells, altered expression and/or cellular localization of HER-specific ligands may represent a previously unrecognized mechanism
determining intrinsic breast cancer resistance/sensitivity to the EGFR TKI gefitinib.
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be selected for treatment with gefitinib on the same basis as
such EGFR mutations have been reported neither in primary
breast carcinomas nor in several breast cancer cell lines
(12,14,15). NSCLCs carrying mutations of the HER1 tyrosine
kinase domain are highly sensitive to gefitinib (reviewed in
ref. 13). Although the rate of mutations in breast cancer patients
remains unclear, Lynch et al did not find any mutations of
HER1 exons 19 and 21 in any of 15 primary breast cancer
samples analyzed nor in the breast cancer-derived cell line
MDA-MB-468 (12). The absence of HER1-activating
mutations in breast carcinomas has also been confirmed by
Bhargava et al (14). Normanno et al recently investigated the
status of the HER1 gene in SK-Br3 and MDA-MB-361 cells
that have not been previously screened for HER1 mutations.
Sequence analysis of the whole HER1 TK domain revealed
no mutations as compared with the wild-type HER1 gene
sequence (15). Alternative mechanisms should be involved in
regulating breast cancer cell responses to gefitinib.
There is a general agreement on the hypothesis that the
occurrence of molecular alterations that activate signal trans-
duction pathways downstream of EGFR might affect the
response to EGFR TKIs in breast carcinomas. In this regard,
it has been hypothesized that the PI-3'K/AKT pathway is the
main signaling pathway involved in the resistance to gefitinib
(16-18; Fig. 1b). Gefitinib treatment has been found to produce
a significant reduction of AKT activation in gefitinib-sensitive
cell lines. On the contrary, inhibition of MAPK1/2 activation
upon gefitinib treatment occurred in cell lines with either high
or low sensitivity to this drug. The main model in which the
role of the PI-3'K/AKT pathway in the resistance to gefitinib
has been explored is the MDA-MB-468 breast cancer cell line.
These cells carry a deletion of the PTEN tumor suppressor
protein leading to constitutive activation of the PI-3'K/AKT
pathway. Moreover, the reconstitution of PTEN function or
inhibition of PI-3'K activity with specific inhibitors can restore
gefitinib sensitivity in MDA-MB-468 cells. This hypothesis
has been confirmed by a pharmacodynamic study of Baselga
et al (20). These authors found that treatment of advanced
breast cancer patients for 28 days with gefitinib produced a
significant inhibition of both HER1 phosphorylation and
MAPK activation but not of AKT activation in tumor tissue,
and this phenomenon was associated with no significant effects
of gefitinib on tumor cell proliferation as measured by Ki67
immunostaining. Evidence also suggests that the MEK/MAPK
pathway might be involved in the spontaneous and acquired
resistance of breast cancer cells to EGFR TKIs (15,19; Fig. 1c).
Normanno et al recently demonstrated the direct involvement
of the MAPK signaling cascade in the resistance of breast
cancer cells to gefitinib (15). In their study, overexpression
of a constitutively activated form of MAPK in MCF10A non-
transformed human mammary epithelial cells resulted in a
2- to 3-fold increase in the IC50 value to gefitinib. In agreement
with this observation, combined treatment with gefitinib and
the MEK inhibitor PD98059 produced a synergistic anti-tumor
effect and also produced a significant increase in the levels
of apoptosis in breast cancer cells with natural resistance
to gefitinib (e.g., MDA-MB-468 cells) as compared with
treatment with a single agent (15). This hypothesis has been
confirmed by Magne et al (19), who showed an association
between intrinsic activation of MAPK signaling and resistance
to gefitinib in head and neck cancer cells. Pre-operative treat-
ment of ER-positive/HER1-positive breast cancer patients with
gefitinib alone or gefitinib plus anastrozole, the only clinical
trial so far demonstrating significant benefits for gefitinib-
containing regimens in breast cancer, produced significant
reduction of MAPK activation and Ki67 labeling index (8).
These hypotheses have been confirmed by pharmacodynamic
studies (20). 
Response to EGFR TKIs might also correlate with the total
levels of expression of the different HER receptors (HER1/-
2/-3/-4). In fact, low levels of EGFR might be sufficient to
trans-activate other HER receptors through the formation
of HER heterodimers and through lateral signaling (21,22).
In this respect, breast cancer cell lines with low levels of
expression of EGFR are extremely sensitive to the anti-tumor
effects of gefitinib, if they co-express high levels of HER2
(16,23-25). This effect has been demonstrated to be mediated,
at least in part, by gefitinib reduction of HER1/HER2 hetero-
dimer phosphorylation (16,23-25).  
3. Ligands of the EGFR network: Forgotten protagonists
in gefitinib resistance
The ligands that bind to and activate the HER family of TKs
are known as EGF-related peptide growth factors. They
exhibit differential receptor binding specificities and are
grouped into three classes: one group of ligands including
EGF, amphiregulin (AR) and transforming growth factor-α
(TGFα) bind specifically to HER1; a second group composed
of ß-cellulin (BTC) and epiregulin (EPR) bind to HER1 and
HER4; and a third group composed of neuregulins (NRG)
bind to HER3 and HER4 (22,27,28). HER2 remains an orphan
receptor, with no soluble ligand identified to date. However,
this receptor occupies a pivotal role in the TK function of the
EGFR network, being the preferred and most potent hetero-
dimerization partner for the other HER receptors (29). 
Because the ligands activate different HER receptors and
most tumors of epithelial origin express multiple HER receptors
and coexpress one or more of the EGF-related ligands, multiple
HER receptor combinations might be active in a tumor. This
characteristic should influence tumor response to an HER-
targeted therapeutic and, therefore, the efficacy of anticancer
drugs that block a single HER receptor may be comprised by
the presence of EGF-related ligands. In this regard, Motoyama
et al demonstrated that the growth-inhibitory effects of
monoclonal antibodies and TKIs targeting HER1 and HER2
are significantly attenuated in the presence of exogenous
ligands (26). However, there are no studies so far addressing
the effects of EGFR TKIs on the endogenous expression of
EFG-related ligands. Using real-time RT-PCR, we recently
characterized MCF-7, MDA-MB-231, MDA-MB-468 and
SK-Br3 breast cancer cell lines according to the mRNA
expression of ligands from the EGF network prior to and after
gefitinib treatment (Table I). When expression data were
normalized relative to ribosomal RNA (18S RNA) as endo-
genous control gene and related to the gefitinib 50% inhibitory
concentration (IC50) in each cell line, we made the following
conclusions.
Low HER1-expressing MCF-7 cells, as expected, were
insensitive to gefitinib (IC50 >20 μM). Interestingly, a subset
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of ligands of the EGF network significantly increased following
gefitinib treatment. Specifically, the mRNA expression of EPR
and NRG, two ligands of the HER3 and HER4 receptors, which
are overexpressed in MCF-7 cells, showed up to 600-fold
increased concentration upon gefitinib exposure.
In agreement with Moasser et al (16), HER1-overexpressing
MDA-MB-231 cells were rather insensitive to the anti-
proliferative effects of gefitinib (IC50 = 18±2 μM), as compared
with the vulvar carcinoma cell line A431, which expresses
~2x106 HER1 receptors/cell and is classically used as a positive
control for anti-HER1 therapies (IC50 = 0.8±2 μM; data not
shown). Of note, gefitinib-treated MDA-MB-231 cells
significantly up-regulated by 6-fold mRNA expression of
BTC, a potent survival factor even in the absence of its HER1
receptor (30). 
MDA-MB-468 cells (IC50 = 15±1 μM), the main ‘HER1-
positive’ breast cancer model of gefitinib resistance via con-
stitutive activation of the intracellular signaling downstream
of the HER1 receptor (i.e., PI-3'K/AKT and MEK/MAPK
pathways) (15-18), provided an interesting comparison. Upon
gefitinib treatment, HER1- and HER3-overexpressing MDA-
MB-468 cells significantly up-regulated (up to 21 times) the
HER1 ligands EGF, AR and BTC as well as the HER3 ligand
NRG.
HER2-overexpressing SK-Br3 breast cancer cells, which
also express HER1 and HER3, were exquisitely sensitive to
gefitinib (IC50 <1 μM). Searching for potential mechanisms
explaining the high sensitivity of SK-Br3 cells to gefitinib,
Anido et al observed that gefitinib promotes the formation of
inactive (unphosphorylated) HER1/HER2 and HER1/HER3
heterodimers (31). Moreover, they found that gefitinib-treated
SK-Br3 cells are no longer stimulated by the non-HER1 ligand
NRG, suggesting that gefitinib also exerts its antitumor effects
by sequestration of HER2 and HER3, a favorite heterodimeriz-
ation partner of HER2, into inactive HER1-based heterodimers
(31). Remarkably, we here found that the HER1 ligand TGFα
was profoundly down-regulated (up to 104 times) following
gefitinib treatment. Moreover, the expression of the HER3
ligand NRG was completely abolished (up to 106 times down-
regulation) in the presence of gefitinib (Table I).
We have partially validated our findings using immuno-
blotting analyses, which likewise demonstrated a significant
modulation of the protein levels of HER-specific ligands
upon gefitinib treatment (data not shown). Collectively, these
findings reveal for the first time the following: a) gefitinib-
induced changes in the expression pattern of genes codifying
for EGF-related ligands strikingly correlate with the intrinsic
degree of sensitivity of breast cancer cells to the antipro-
liferative effects of gefitinib; i.e., gefitinib-resistant and
gefitinib-sensitive breast cancer cells markedly up-regulate
and down-regulate, respectively, the expression of genes
codifying for EGF-related ligands; and b) gefitinib exposure
appears to regulate HER ligand gene clusters in an HER
receptor-dependent manner; i.e., gefitinib-treated breast cancer
cells specifically modulate the gene expression of EGF-related
ligands with high affinity to the set of HER receptors present
in the cells.
These findings suggest that activation/deactivation of
HER ligand gene clusters might balance loss of HER receptor
function and, therefore, may represent a previously unrecog-
nized mechanism determining intrinsic breast cancer resistance/
sensitivity to the EGFR TKI gefitinib. 
4. Gefitinib and the HER network: From the cell surface
to the nucleus
Both intrinsic and acquired resistance to EGFR inhibitors have
been identified as potential treatment obstacles for patients
receiving HER receptor-directed therapeutics. In vitro and
pharmacodynamic studies support a role for the signaling
pathways downstream of the EGFR (i.e., PI-3'K/AKT and
MEK/MAPK) in the intrinsic resistance of breast cancer cells
to gefitinib (5-20). We here report the selective increase in the
expression of genes codifying for growth factors of the EGF
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Table I. Gene expression profiles for ligands of the EGF network following gefitinib treatment.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
HER receptor status Gefitinib-induced changes in HER-specific ligands
––––––––––––––––––––––––– –––––––––––––––––––––––––––––––––––––––––––––––
HER1 ligands HER1/4 ligands HER3/4 ligand
–––––––––––––––– –––––––––––––
Gefitinib IC50 HER1 HER2 HER3 HER4 EGF AR TGFα BTC EPR NRG
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
MCF-7 21±2 μM -/+ + +++ +++ +12 n.d. +7 n.d. +600 +18
MDA-MB-231 18±2 μM +++ -/+ -/+ -/+ n.d. -2 -3 +6 n.d. -2
MDA-MB-468 15±1 μM +++ -/+ ++ -/+ +21 +9 n.d. +12 n.d. +8
SK-Br3 1±0.2 μM ++ +++ ++ -/+ n.d. n.d. -104 n.d. n.d. -106
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
-/+, negative/weak; ++, moderate; +++, strong; n.d., not determined. Using real-time RT-PCR, MCF-7, MDA-MB-231, MDA-MB-468 and
SK-Br3 breast cancer cell lines were characterized according to the mRNA expression of ligands from the EGF network prior and after
gefitinib treatment (3 days). Data indicate x-fold changes in the expression of genes codifying for EGF-related ligands by comparing with
control (DMSO-treated) cells. The metabolic status of gefitinib-treated cells was first evaluated using an MTT-based cell viability assay and
constructing dose-response curves. Gefitinib concentrations required to produce the IC50 value (the drug concentration needed to reduce cell
viability by 50% relative to untreated control cells) were calculated by interpolation. HER receptor status was characterized by immunoblotting
and ELISA procedures and yielded equivalent results to those previously reported by Moasser et al (16).
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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network as a previously unrecognized molecular response of
breast cancer cells naturally resistant to gefitinib. Interestingly,
breast cancer cells with acquired resistance to the anti-HER2
monoclonal antibody trastuzumab (Herceptin®) express higher
levels of EGF-related ligands as compared with parental,
trastuzumab-sensitive cells (32). Therefore, the intrinsic or
acquired ability of breast cancer cells to specifically regulate
HER ligand gene clusters may represent a common molecular
mechanism determining the efficacy of anticancer drugs
blocking a single HER receptor. 
An intriguing question, however, arises from the above
hypothesis. If an overproduction of EGF-related growth factors
actively rescues the antiproliferative effects of gefitinib, we
should expect ligand-induced activation of other HER family
members and reactivation of downstream signaling pathways
upon gefitinib exposure, which does not occur. How can we
reconcile these conflicting findings? Firstly, mitogenic growth
factors including EGF-related ligands are generally considered
cell surface-associated or secreted proteins, which produce
effects by binding to cell surface receptor TKs. However,
evidence is mounting that several members of the HER
receptor ligand family can translocate to the nucleus and,
more importantly for this study, they play a role in the etiology,
progression and chemosensitivity of breast cancer by mech-
anisms independent of HER receptor activation (33-37).
Secondly, like other receptor TKs located in the cell membrane,
the members of the EGFR TK family are conventionally
considered as integral membrane molecules transferring signals
through the cell membrane. However, members of the HER
receptor family have also an important role directly within
the nucleus. For instance, it now appears that a direct mode
of EGFR signaling in which EGF shuttles its HER1 receptor
into the nucleus, results in transcriptional activation of target
genes (38,39). Recent studies have also revealed the presence
of HER2 in the nucleus of breast cancer cells and identified
the HER2 nuclear function as a transcriptional regulator
(40,41).
The well-established traditional function of the HER
signaling pathway is known to transmit extra-cellular mitogenic
signals from EGF-related ligands through activating a number
of downstream signaling cascades. In cancer cells, the common
outcomes following the activation of the HER network are
altered gene activities, leading to uncontrolled tumor prolifer-
ation and apoptosis. As described above, emerging evidence
suggests the existence of a novel ‘direct mode’ involving
cellular transport of HER receptors or HER ligands to the
cell nucleus, their association with gene promoters, and tran-
scriptional regulation of target genes (36,42-44). Auspiciously
suggested by Lo et al (43,44), a better understanding of this
new ‘nuclear mode’ of the HER network will facilitate the
identification of patients that are likely to respond to anti-
HER agents as well as future development of more effective
therapeutic interventions aimed to block the HER pathway.
An active role of nuclear HER receptors in the response of
breast cancer to chemotherapy- and radiotherapy-induced
cell damage has already been established (40,41). However,
little is known about the role of nuclear EGF-related ligands on
the response of breast cancer cells to HER-targeted therapies.
Nevertheless, the relevance of this mechanism warrants further
studies as breast cancer cells could bypass the antiproliferative
effects of a HER1-directed inhibitor without a need for the
overexpression and/or activation of HER family members and/
or activation of HER-driven downstream signaling cascades. 
In a first attempt to reveal gefitinib-induced changes in
the nuclear mode of the HER network, we recently assessed
the cellular accumulation and compartmentalization of the
EGF-related ligand NRG prior to and after gefitinib treatment
using immunofluorescence microscopy. NRG was shown
recently to localize to the nuclei of human breast cancer cells
in a receptor-independent manner, supporting the notion that
secretion and subsequent cell surface receptor binding of some
HER-ligands are not a prerequisite for nuclear localization
and that nonsecreted HER-ligands may have highly specific
functions in defined nuclear compartments (35,36). Indeed,
indirect immunofluorescent studies with an anti-NRG antibody
revealed a prevalent nuclear localization of endogenous NRG
in MDA-MB-468 and SK-Br3 breast cancer cell lines (Fig. 2).
Remarkably, this pattern of sub-nuclear dot formation of
endogenous NRG was significantly affected upon gefitinib
treatment. Gefitinib-resistant MDA-MB-468 cells exhibited a
striking nuclear accumulation of NRG following gefitinib
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Figure 2. Gefitinib treatment modifies nuclear accumulation of the HER-
specific ligand NRG. Gefitinib (Iressa)-resistant MDA-MB-468 breast
cancer cells grown on cover-slides in the absence or presence of 10 μM
gefitinib (48 h) were fixed for 15 min in PBS containing 2% paraformaldehyde
and then permeabilized in PBS containing 0.2% Triton X-100 for 5 min,
washed with PBS, and post-fixed for 20 min in 100% methanol at -20˚C.
After two washes with PBS, cells were blocked in PBS containing 5 mg/ml
BSA and 20 mM Glycine for 30 min. Cells were stained with an anti-NRG
antibody (1:100 dilution, 1 h, room temperature; C-20, sc-348, Santa Cruz
Biotech., Santa Cruz, California, USA) followed by TRITC-conjugated anti-
rabbit IgG antibody (45 min, room temperature), both of which were diluted
with PBS containing 5 mg/ml BSA. DNA was stained with diamidino-2-
phenylindole (DAPI). Stained cells were observed and analyzed using a Nikon
Eclipse E800 microscope equipped for epifluorescence. A representative
immunofluorescence is shown (n=3). 
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exposure (Fig. 2). Conversely, gefitinib treatment significantly
reduced dot-like structures containing NRG in the nuclei of
gefitinib-sensitive SK-Br3 breast cancer cells (data not shown).
Considering that nuclear accumulation of endogenous NRG
is not a passive diffusion process (36), the above findings are
extremely relevant as they clearly implicate that loss of HER1
function differentially regulates an active nucleo-cytoplasmic
trafficking of NRG in gefitinib-resistant and -sensitive breast
cancer cells, respectively. 
At present, it is unclear what all the NRG-regulated nuclear
functions are, and which of them could play a role in the
response of breast cancer to gefitinib-induced cell damage.
Interestingly, nuclear NRG has been shown to specifically
interact with several proteins implicated in transcriptional
regulation, including the transcriptional repressor histone
deactylase 2 (HDAC2) (36). Using cDNA microarrays,
Chinnaiyan et al recently identified HDAC inhibitors as
having strong potential to enhance the effects of anti-HER
agents (45). Moreover, when used cooperatively, HDAC
inhibitors and gefitinib treatment has been suggested a
valuable pharmacological strategy for overcoming resistance
to HER1 inhibitors in patients with lung cancer (46). Further
investigations should determine whether a causal connection
exists between an enhanced or reduced presence of ‘nuclear
HER ligands’ such as NRG, their interaction with target genes
and/or protein such as HDAC, and breast cancer cell responses
to gefitinib. Nevertheless, this is the first report showing that
pharmacological inhibition of HER1 function leads to signifi-
cant changes in both the expression and the nucleo-cytoplasmic
trafficking of EGF-related ligands, and that these changes
correlate with the intrinsic degree of breast cancer sensitivity
to gefitinib. 
5. Clinical perspectives
Overall clinical response rates to EGFR TKIs are extremely
low in breast cancer, often in the range of 5-20%. Landmark
studies indicate that a cohort of lung cancer patients harbor
specific EGFR mutations that play a significant role in
determining tumor sensitivity/resistance to gefitinib (10-13).
However, preliminary findings suggest that such mutations do
not occur in breast carcinomas cells (12,14,15). Therefore, it
is unlikely that breast cancer patients might be selected for
treatment with gefitinib on the basis of EGFR mutations.
Indeed, it is unclear at this time how to select a breast cancer
patient population most likely to be sensitive to gefitinib. 
Although we are lacking retrospective studies evaluating
the response to gefitinib treatment in breast carcinomas with
known content of both HER1 and EGF-related growth factors,
and caution must be applied when extrapolating in vitro
results into clinical practice, it is reasonable to suggest that a
correct molecular pathological analysis of breast carcinomas
should incorporate the detection of EGF-related ligands and
their intracrine, autocrine and/or paracrine actions as clinical
valuable markers in gefitinib-based regimens (Fig. 1d and e).
Although we acknowledge that additional experiments are
required (e.g., siRNA evaluation of the impact of the up-
regulation HER ligands on the EGFR inhibitor-resistant breast
cancer phenotype), our current findings strongly suggest that
gefitinib-resistant breast cancer cells retain the ability to
compensate for loss of HER1 receptor function by significantly
up-regulating EGF-related ligands. Therefore, dual assays
monitoring the expression profile and the sub-cellular localiz-
ation not only of HER receptors but also of HER-specific
ligands might be more useful than a single assay to identify
responders among breast cancer patients receiving HER
receptor-targeted anticancer therapeutics. In this regard, we
recently demonstrated that breast cancer cells naturally or
ectopically overexpressing the HER3 ligand NRG and single-
copy low levels of HER2 are unexpectedly hypersensitive to
chemotherapy when co-treated with the anti-HER2 mono-
clonal antibody trastuzumab, while this sensitizing effect was
mimicked by transfection of an antisense cDNA against the
HER3/HER4 ligand NRG (47). These results and our current
findings strongly reaffirm the role of ligand-induced signal
amplification in mediating HER-dependence in breast cancer
and, in agreement with a recent editorial by Arteaga, further
highlight the need of incorporate HER ligands to the molecular
profile obtained in tumors/patients enrolled in trials with drugs
targeted against HER1, HER2 or HER3 (48). 
6. Conclusions
According to Mendelsohn's hypothesis, formulated in the early
1980s, the pharmacological blockade of HER1 activation
may be able to inhibit cancer proliferation, and cancer cells
may be selectively sensitive to HER1 inhibition as compared
to normal cells (49). We have learned that simple measurement
of HER1 expression is not predictive of the activity of HER1
inhibitors, including gefitinib (50). Besides mutations in the
HER1 gene that make the target sensitive or resistant to
gefitinib, studies have revealed that additional oncogenic
changes downstream of HER1 could also result in resistance
to EGFR TKIs (50). According to the conventional approach,
the main strategy to overcome resistance to anti-HER1 drugs
should be to combine such agents with inhibitors of the
intracellular signaling downstream of HER1. ‘Cyclotherapy’,
an elegant therapeutic approach recently proposed by
Blagosklonny and Darzynkiewicz, further suggests that the
combination of low doses of gefitinib with cycle-dependent
and apoptosis-inducing chemotherapies will be most beneficial
to patients who do not respond to monotherapy with HER1
TKIs (51,52). Unfortunately, virtually nothing is known on
what the autocrine and/or paracrine actions of HER ligands
involved in the efficacy of gefitinib are. Furthermore, the
intracrine actions of HER-specific ligands, bypassing the
antiproliferative effects of gefitinib without a need for the
overexpression and/or activation of HER receptors and/or
the activation of HER receptor-driven downstream signaling
cascades, has not been considered as a molecular mechanism
underlying natural cancer cell resistance to gefitinib. Our
current findings provide evidence that gefitinib treatment
leads to significant changes in both the gene expression and
the nucleo-cytoplasmic trafficking of EGF-related ligands,
and that these changes correlate with the intrinsic degree of
breast cancer cell sensitivity to gefitinib. We are conscious that
this ‘direct mode’ involving active transport of HER-ligands
to the cell nucleus, their association with gene promoters, and
transcriptional regulation of target genes may add even more
complexity to the ‘gefitinib scenario’, but it should offer a
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novel rationale for a better molecular understanding and a
more correct use of HER1-targeted therapeutics in breast
cancer. 
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